Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | ACHE | P22303 | 4/20 | 0.51 |
| ▸ | MAOB | P27338 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.50 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.50 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 3/20 | 0.49 |
| ▸ | EGFR | P00533 | 2/20 | 0.49 |
| ▸ | XBP1 | P17861 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3314444 | 0.93 | PKM (0.55) | KDM4EPKMACHEMAOBMAPT | |
| SCHEMBL3311133 | 0.91 | MAOB (0.58) | KDM4EPKMACHEMAOBMAPT | |
| SCHEMBL3314961 | 0.89 | XBP1 (0.60) | KDM4EPKMACHEMAOBABCB1 | |
| SCHEMBL3310763 | 0.83 | PKM (0.57) | KDM4EPKMACHEMAOBP2RY6 | |
| SCHEMBL3318263 | 0.79 | KDM4E (0.71) | KDM4EPKMMAPTBLMP2RY6 | |
| SCHEMBL3314554 | 0.79 | XBP1 (0.57) | KDM4EPKMMAPTBLMABCB1 | |
| SCHEMBL3312789 | 0.78 | KDM4E (0.65) | KDM4EPKMMAPTBLMP2RY6 | |
| SCHEMBL3316509 | 0.78 | XBP1 (0.76) | KDM4EPKMMAPTBLMP2RY6 | |
| SCHEMBL3312460 | 0.77 | MAOB (0.78) | KDM4EPKMACHEMAOBMAOA | |
| SCHEMBL3318087 | 0.77 | KDM4E (0.63) | KDM4EPKMMAPTBLMP2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105729-A1 | ARYL-SUBSTITUTED HETEROCYCLIC PDE4 INHIBITORS AS ANTI-INFLAMMATORY AGENTS | KALYPSYS, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100105729-A1 | ARYL-SUBSTITUTED HETEROCYCLIC PDE4 INHIBITORS AS ANTI-INFLAMMATORY AGENTS | KALYPSYS, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| WO-2008045663-A2 | ARYL-SUBSTITUTED HETEROCYCLIC PDE4 INHIBITORS AS ANTIINFLAMMATORY AGENTS | KALYPSYS, INC. (US) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105729-A1 | ARYL-SUBSTITUTED HETEROCYCLIC PDE4 INHIBITORS AS ANTI-INFLAMMATORY AGENTS | PDE4A, PDE4B, PDE4C | KDM4E 332/4885PKM 2178/4885ACHE 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.